Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: J Immunother. 2021 Oct 1;44(8):283–291. doi: 10.1097/CJI.0000000000000379

Figure 4: DFMO/anti-PD-1 combination therapy potently alters tumoral CD8+ T cell viability through an indirect mechanism.

Figure 4:

(A) Phenotypic flow cytometry analysis of CD8+ T cell populations within B16/F10 tumors in 4 treatment cohorts. (B) In vitro analyses of PMA/ionomycin activated T cell (Jurkat cell line) proliferation in 10mM DFMO and/or 80μM putrescine over 72 hours (top; total cell counts normalized to 72HR controls) and MTT signal at 72 hours post-treatment (bottom; absorbance (A595) normalized to control). (C) Quantification of activation-induced cell death (AICD) via trypan blue counts of Jurkat cultures 24 hours post activation. Values represent ratio of Living (Trypan−) to Total cells in each culture condition.